Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain demand-led clinical supply services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. Catalent, Inc. was incorporated in 2007 and is headquartered in Somerset, New Jersey.

Catalent, Inc.

Statement of Changes in Beneficial Ownership

Amended Statement of Changes in Beneficial Ownership

Initial Statement of Beneficial Ownership

Insider	Title	Transaction Type	Shares Traded	% of Shares Traded	% Chg. in Shares	End of Filing Shares	Price	Transaction Value	Filing Date	Transaction Date
Ricky Hopson	President, Division Head for BioProduct Delivery & Chief of Staff Show All	Open Market Disposition (Sale)	-662	-0.000365%	-2.16%	29.97K	$59.56 - $59.56	-$39.43K	05 Aug 2024	02 Aug 2024 - 02 Aug 2024
Scott Gunther	Senior Vice President of Quality & Regulatory Affairs Show All	Open Market Disposition (Sale)	-666	-0.000367%	-1.65%	39.64K	$59.55 - $59.55	-$39.66K	05 Aug 2024	02 Aug 2024 - 02 Aug 2024
Joseph A. Ferraro	Senior VP, General Counsel, Chief Compliance Officer & Secretary, Senior VP, General Counsel, Chief Compliance Officer & Corporate Secretary Show All	Open Market Disposition (Sale)	-608	-0.000335%	-35.45%	1.11K	$59.58 - $59.58	-$36.23K	05 Aug 2024	02 Aug 2024 - 02 Aug 2024
Lisa Evoli	Senior VP & Chief Human Resources Officer Show All	Open Market Disposition (Sale)	-3.86K	-0.002132%	-41.51%	5.44K	$59.67 - $59.67	-$230.27K	05 Aug 2024	02 Aug 2024 - 02 Aug 2024
Aristippos Gennadios	Group President of Pharma & Consumer Health Segment, President of Softgel & Oral Technologies Show All	Open Market Disposition (Sale)	-1.17K	-0.000645%	-1.02%	113.72K	$59.55 - $59.55	-$69.61K	05 Aug 2024	02 Aug 2024 - 02 Aug 2024
John J. Greisch
Michael J. Hatzfeld
David McErlane
Joseph A. Ferraro
Lisa Evoli
Matti M. Masanovich
Alessandro Maselli
Alessandro Maselli
Ricky Hopson
Ricky Hopson
Scott Gunther
Scott Gunther
Aristippos Gennadios
Aristippos Gennadios
Matti M. Masanovich
Ricky Hopson
Scott Gunther
Christa Kreuzburg
Michael J. Hatzfeld
Michael J. Hatzfeld
Aristippos Gennadios
Aristippos Gennadios
Alessandro Maselli
Alessandro Maselli
Scott Gunther